Capricor Therapeutics, Inc.
NASDAQ:CAPR
Overview | Financials
Company Name | Capricor Therapeutics, Inc. |
Symbol | CAPR |
Currency | USD |
Price | 14.13 |
Market Cap | 642,489,687 |
Dividend Yield | 0% |
52-week-range | 3.52 - 23.4 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Linda Marbán Ph.D. |
Website | https://www.capricor.com |
An error occurred while fetching data.
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD